Topical Oestrogen in the UK: What's Available and How It's Used

When women search for vaginal or topical oestrogen, the questions are usually practical: what forms exist, how are they used, and is it the same as taking HRT? Those are good questions, and the UK answers to them are clearer than the silence around the topic suggests. This article looks specifically at the UK-availability angle — what's on the shelf, what changed recently, and how these treatments are used. It is not the fuller piece on why genitourinary symptoms are so undertreated; I've written that separately. Here, the lens is simply: what's available, and how it works.

What forms of topical oestrogen are available in the UK?

In the UK, low-dose topical oestrogen for menopausal genitourinary symptoms comes in a few forms: creams, vaginal tablets or pessaries, and a vaginal ring. They differ in how they're applied and how often, but they share the same basic job — delivering a small dose of oestrogen directly to the vaginal tissue.

Creams and gels are applied with an applicator, typically more frequently at first and then less often as a maintenance routine. Vaginal tablets and pessaries are small inserts used on a similar pattern — a short daily phase, then a couple of times a week. The vaginal ring is a soft, flexible ring placed in the vagina that releases a low dose steadily over a period of months before being replaced. Which form suits a person is partly clinical and partly preference; the common feature across all of them is that they act locally, on the tissue, rather than dosing the whole body.

What are these treatments actually for?

They treat the genitourinary syndrome of menopause — the cluster of symptoms that arises as oestrogen falls and the tissues of the vulva, vagina, urethra and bladder become thinner, drier and less elastic.

As oestrogen declines, these oestrogen-rich tissues change: they lose thickness, elasticity and blood supply, and the natural acidity that protects the vaginal microbiome shifts, making infections more likely. The result is a recognisable set of symptoms — vaginal dryness, itching or burning, discomfort or pain during sex, and on the urinary side, urgency, frequency, discomfort passing urine, and recurrent urinary tract infections. Crucially, unlike hot flushes, this tends not to settle on its own; it reflects an ongoing tissue change, which is why a treatment that addresses the tissue directly is so useful. Topical oestrogen restores some of that thickness, elasticity, blood supply and acidity at source.

Is topical oestrogen the same as HRT?

No — and this is the point that resolves most of the worry. Low-dose topical vaginal oestrogen is designed to act on the local tissue, and at the doses used, systemic absorption — the amount reaching the rest of the body through the bloodstream — is minimal.

This is the central reason its safety profile differs markedly from systemic HRT. Blood oestrogen levels generally remain within the normal postmenopausal range, so the considerations that complicate the systemic HRT conversation apply quite differently. UK and specialist guidance reflects this: low-dose vaginal oestrogen is regarded as suitable for the great majority of postmenopausal women, can generally be used long term (the symptoms return if it's stopped, because the underlying tissue change persists), and usually does not require the addition of a progestogen for womb protection in the way systemic oestrogen does, because so little reaches the womb lining. Women with a history of breast cancer are a group where the decision is more individual and best made with their specialist — a genuine nuance, not a blanket bar. None of this is a "risk-free" claim; it is a different, and generally reassuring, risk profile from systemic treatment.

What changed recently in the UK?

One specific low-dose vaginal oestrogen product moved from prescription-only to availability from pharmacies — meaning, for that particular product, a pharmacist can supply it directly after an appropriate consultation, rather than it requiring a prescription every time.

This reclassification was made on the basis that low-dose vaginal oestrogen is well understood, has minimal systemic absorption, and can be supplied safely with pharmacist involvement and clear criteria. It is worth being precise about what it does and doesn't change. It improves access for suitable women and brings a pharmacist's assessment into the process; it does not turn the treatment into an off-the-shelf grab, and it does not remove the need for clinical judgement about whether it's appropriate or whether symptoms need fuller assessment. The pharmacist consultation is part of the safeguard, not a bypass of it.

The red flag that overrides everything

There is one symptom in this territory that is never to be assumed away as "just dryness" or "just the menopause": bleeding after the menopause.

Any vaginal bleeding more than twelve months after a woman's last period — postmenopausal bleeding — needs medical assessment. In most cases the cause turns out to be benign, including the fragile tissues of the genitourinary syndrome itself. But postmenopausal bleeding is also the cardinal symptom of endometrial (womb) cancer, and it cannot be told apart from a harmless cause without proper assessment. This holds regardless of whether a woman is using topical oestrogen. The rule is simple and worth stating plainly: new bleeding after the menopause is always a reason to be seen, not to wait and see.

Practical takeaways

• UK topical oestrogen for menopausal symptoms comes as creams, vaginal tablets or pessaries, and a vaginal ring — all delivering a low dose locally to the tissue.
• They treat the genitourinary syndrome of menopause — dryness, discomfort, urinary urgency and recurrent UTIs — which, unlike hot flushes, doesn't resolve on its own.
• At the low doses used, systemic absorption is minimal, so the safety profile differs from systemic HRT; it can usually be used long term and often without a progestogen.
• One low-dose vaginal oestrogen product moved to pharmacy availability, improving access with a pharmacist's assessment — not removing the need for clinical judgement.
• Any bleeding after the menopause needs assessment, every time, regardless of any treatment in use.

What this doesn't mean

It doesn't mean topical oestrogen is risk-free, or that "minimal systemic absorption" means zero — it doesn't, and certain women, those with a history of breast cancer in particular, have a more individual decision to make. Nor does pharmacy availability mean the treatment suits everyone or replaces a proper assessment when symptoms warrant one. The point is that the options exist, work, and are too often never raised — not that the answer is automatically yes.

When to seek medical advice

Raise genitourinary symptoms with a GP, practice nurse or pharmacist if they're affecting comfort, intimacy or urinary health — they're treatable, and pharmacy availability has made the first conversation easier than it used to be. Seek prompt assessment for any bleeding after the menopause, for recurrent urinary infections, or for new pain, and don't let embarrassment be the reason a treatable problem goes untreated.

A closing thought

The UK picture here is quietly encouraging: several effective forms, a safety profile that reassures most women once it's explained, and a recent move that puts one option within easier reach. What hasn't changed is the part that depends on a person and a clinician — knowing whether it's right for you, and never ignoring a postmenopausal bleed. Easier access is a genuine improvement; it works best alongside the conversation, not instead of it.

Further reading and sources

• NICE NG23 — Menopause: diagnosis and management
• British Menopause Society — guidance on urogenital atrophy and vaginal oestrogen
• MHRA — reclassification of a low-dose vaginal oestrogen product to pharmacy availability
• NHS — vaginal dryness, menopause, and topical oestrogen information
• Royal College of Obstetricians and Gynaecologists — patient information on postmenopausal bleeding

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.